TEVA
NYSETeva Pharmaceutical Industries Limited
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$38.10+0.76 (+2.04%)
01:30 PM07:45 PM
News · 26 weeks99+14%
2026-03-012026-08-23
Mix4690d
- Insider28(61%)
- Other12(26%)
- SEC Filings3(7%)
- Earnings3(7%)
Latest news
25 items- INSIDERChief Accounting Officer Weiss Amir sold $355,301 worth of Ordinary Shares (9,445 units at $37.62) and exercised 2,500 units of Ordinary Shares at a strike of $19.61, decreasing direct ownership by 35% to 13,071 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Satchi-Fainaro Ronit sold $15,459 worth of Ordinary Shares (415 units at $37.25), decreasing direct ownership by 0.37% to 111,986 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDEREVP, Business Development Lippman Evan sold $680,291 worth of Ordinary Shares (18,600 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 42% to 25,591 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRU.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette SyndromeEcopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designationNDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b dataIf approved, ecopipam would be the first new treatment option indicated for pediatric patients with Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years1 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application
- PRMoody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth StrategyTEL AVIV, Israel, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Moody’s Ratings has upgraded Teva’s corporate credit rating to Baa3 from Ba1, an investment-grade rating, with a stable outlook. Moody’s states that the upgrade reflects the ongoing success of Teva’s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody’s also noted Teva’s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months. "Moody’s upgrad
- INSIDERDirector Zaks Tal Zvi sold $593 worth of Ordinary Shares (17 units at $34.87), decreasing direct ownership by 0.02% to 73,247 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Jover Placid converted options into 12,827 units of Ordinary Shares and sold $447,351 worth of Ordinary Shares (12,827 units at $34.88) as part of a pre-agreed trading plan (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERSee "Remarks" Hughes Eric A converted options into 52,744 units of Ordinary Shares and sold $892,051 worth of Ordinary Shares (25,578 units at $34.88) as part of a pre-agreed trading plan, increasing direct ownership by 25% to 134,877 units (SEC Form 4) (for withholding tax)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- SECSEC Form 10-Q filed by Teva Pharmaceutical Industries Limited10-Q - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- SECTeva Pharmaceutical Industries Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
- PRTeva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth StrategyQ2 2026 revenues of $4.1 billion decreased by 1% in U.S. dollars year-over-year (YoY) and by 3% in local currency (LC) terms, mainly due to lower generics revenues. Our key innovative brands collectively grew 43% YoY in LC, to over $1 billion in revenues, and we raised our 2026 outlook for all three, highlighting Teva’s continued execution of its Pivot to Growth strategy.Key Innovative brands continued to drive growth while transforming Teva’s portfolio mix and financial profile: AUSTEDO® continued to grow rapidly, with global revenues of $696 million, growing 40% YoY in LC.AJOVY® global revenues of $244 million, increasing 56% YoY in LC.UZEDY® revenues of $77 million, increasing 43% YoY in
- PRTeva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisTeva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations. Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimi
- PRTeva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple SclerosisTeva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commerci
- PRTeva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in CanadaTORONTO, Canada and INCHEON, South Korea, July 9, 2026 /CNW/ - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that the companies have entered into a license and commercialization agreement for OPUVIZ® (aflibercept), a biosimilar referencing Eylea®1 (aflibercept), in Canada. Under the agreement, Samsung Bioepis is responsible for registration and manufacture of the products, while Teva Canada (a subsidiary of Teva Pharmaceutical Industries Ltd.) is responsible for commercialization."This agreement is an important step in strengthening our biosimilars portfolio in Canada
- PRTeva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b ResultsTeva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of patients reported improvement in facial vitiligo, with half reporting "much’ or "very much" improvedTEV-’408 is designed for convenient quarterly (Q12W) subcutaneous dosing Teva will hold an investor call and live webcast today,Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data. TEL AVIV, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an investigational anti-interleukin-15 monoclonal
- INSIDEREVP, Global Operations Shields Matthew sold $321,547 worth of Ordinary Shares (9,989 units at $32.19), closing all direct ownership in the company (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva Releases Q2 2026 Aide MemoireTEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the "Investors" page on its website. Q2 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of second quarter 2026 results, which are expected to be released on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day. This document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Tev
- PRTeva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette SyndromeNDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designationsEcopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved. TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndr
- PRTeva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ETTEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webcast will be
- INSIDEREVP, Chief Financial Officer Kalif Eliyahu Sharon sold $3,633,308 worth of Ordinary Shares (106,563 units at $34.10) as part of a pre-agreed trading plan, decreasing direct ownership by 62% to 65,621 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- PRTeva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth StrategyEcopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations. The acquisition expands Teva's innovative pipeline in a specialized area of neuroscience with significant unmet need and is expected to support near- and long-term growth. At closing, Teva paid $700 million consideration with the potential for up to an additional $200 million in commercial milestone payments, as well as net sales-based royalties, upon commercialization and subject to regulatory approval. TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva P
- INSIDERDirector Barer Sol J converted options into 21,739 units of Ordinary Shares, increasing direct ownership by 5% to 448,011 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Lichtenstein Chen converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 302% to 19,296 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Crane Rosemary A converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 13% to 127,739 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
- INSIDERDirector Elstein Amir converted options into 14,492 units of Ordinary Shares, increasing direct ownership by 0.69% to 2,118,455 units (SEC Form 4)4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
TEVA FAQ
6 questionsWhat does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology...Where does TEVA stock trade?
Teva Pharmaceutical Industries Limited (TEVA) is listed on NYSE.What sector and industry is TEVA in?
Teva Pharmaceutical Industries Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TEVA?
Teva Pharmaceutical Industries Limited has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $3500.00 price target on 2025-12-09. Recent price targets range from $1400.00 to $3500.00.What companies are similar to TEVA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TEVA side-by-side with any of them on Quantisnow.How can I track TEVA on Quantisnow?
Quantisnow aggregates Teva Pharmaceutical Industries Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TEVA to receive live email and push alerts on every new disclosure.